Eupraxia Pharmaceuticals Inc (EPRX)

Nov 16, 2024

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Rodman & Renshaw - Defense World

Nov 16, 2024

Nov 15, 2024

Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024

Nov 15, 2024

Eupraxia Pharmaceuticals files report with SEC - Investing.com

Nov 15, 2024

Nov 15, 2024

RODMAN&RENSHAW Upgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to "Strong-Buy" - MarketBeat

Nov 15, 2024

Nov 15, 2024

Rodman & Renshaw rates Eupraxia stock Buy on 'groundbreaking delivery tech' - Investing.com Canada

Nov 15, 2024

Nov 14, 2024

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting - BioSpace

Nov 14, 2024

Nov 14, 2024

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Rodman & Renshaw - MarketBeat

Nov 14, 2024

Nov 14, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 - PR Newswire

Nov 14, 2024

Nov 13, 2024

Eupraxia Pharmaceuticals reports regulatory update - Investing.com

Nov 13, 2024

Nov 13, 2024

Newswire - KelownaNow

Nov 13, 2024

Nov 12, 2024

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - Quantisnow

Nov 12, 2024

Nov 07, 2024

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - Quantisnow

Nov 07, 2024

Nov 07, 2024

Finansavisen - Finansavisen

Nov 07, 2024

Nov 07, 2024

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 5.4%What's Next? - MarketBeat

Nov 07, 2024

Nov 06, 2024

Troutman Pepper Advises Eupraxia Pharmaceuticals in Closing of a Non-Brokered Private Placement - Troutman Pepper

Nov 06, 2024

Nov 01, 2024

Eupraxia Pharmaceuticals Shares Rise After Completing Private Placement - MarketWatch

Nov 01, 2024

Oct 31, 2024

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - Quantisnow

Oct 31, 2024

Oct 31, 2024

Microstrategy Cl A (MSTR-Q) QuotePress Release - The Globe and Mail

Oct 31, 2024

Oct 28, 2024

Eupraxia Pharmaceuticals Inc. - Baystreet.ca

Oct 28, 2024

Oct 28, 2024

Eupraxia Pharmaceuticals Inc (EPRX-T) QuotePress Release - The Globe and Mail

Oct 28, 2024

Oct 28, 2024

Fennec Pharmaceuticals Inc. - Baystreet.ca

Oct 28, 2024

Oct 28, 2024

Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart

Oct 28, 2024

Oct 28, 2024

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 - Quantisnow

Oct 28, 2024

Oct 16, 2024

Eupraxia reports Phase 2b trial success for osteoarthritis treatment - Investing.com India

Oct 16, 2024

Oct 16, 2024

Eupraxia reports Phase 2b trial success for osteoarthritis treatment By Investing.com - Investing.com Canada

Oct 16, 2024

Oct 16, 2024

Health Rounds: Steroid injection relieves knee arthritis pain for months - Reuters

Oct 16, 2024

Oct 15, 2024

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis - StockTitan

Oct 15, 2024

Oct 12, 2024

Stocks In Play: Eupraxia Pharmaceuticals Inc. - Barchart

Oct 12, 2024

Oct 12, 2024

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 3.4%What's Next? - MarketBeat

Oct 12, 2024

Oct 11, 2024

Eupraxia Pharmaceuticals reports to SEC on latest developments - Investing.com India

Oct 11, 2024

Oct 10, 2024

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results - Barchart

Oct 10, 2024

Oct 10, 2024

Eupraxia Pharmaceuticals reports to SEC on latest developments By Investing.com - Investing.com South Africa

Oct 10, 2024

Oct 10, 2024

Eupraxia Pharmaceuticals Highlights Innovation at UEG Week 2024 - TipRanks

Oct 10, 2024

Oct 10, 2024

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 - PR Newswire

Oct 10, 2024

Oct 09, 2024

EPRX stock touches 52-week low at $2.34 amid market challenges - Investing.com Australia

Oct 09, 2024

Oct 08, 2024

EPRX stock touches 52-week low at $2.34 amid market challenges By Investing.com - Investing.com South Africa

Oct 08, 2024

Oct 04, 2024

eupraxia pharmaceuticals inc. Earnings dates - RTTNews

Oct 04, 2024

Oct 02, 2024

Eupraxia Pharmaceuticals expands leadership team - Investing.com India

Oct 02, 2024

Oct 02, 2024

Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com Canada

Oct 02, 2024

Oct 02, 2024

Eupraxia Pharmaceuticals expands leadership team By Investing.com - Investing.com South Africa

Oct 02, 2024

Oct 02, 2024

Eupraxia Pharmaceuticals Enhances Leadership Team - TipRanks

Oct 02, 2024

Oct 02, 2024

Eupraxia Pharmaceuticals Strengthens Senior Management Team – Company Announcement - Financial Times

Oct 02, 2024

Sep 23, 2024

Mutual of America Capital Management LLC Sells 1,218 Shares of Euronet Worldwide, Inc. (NASDAQ:EEFT) - Defense World

Sep 23, 2024

Sep 22, 2024

Itau Unibanco Holding S.A. Buys New Position in Edwards Lifesciences Co. (NYSE:EW) - Defense World

Sep 22, 2024

Sep 22, 2024

Amalgamated Bank Grows Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World

Sep 22, 2024

Sep 19, 2024

Eupraxia Pharmaceuticals Showcases Innovative Therapy at ISDE Congress - TipRanks

Sep 19, 2024

Sep 19, 2024

Eupraxia Pharmaceuticals to present at ISDE Congress for Esophageal Diseases - TipRanks

Sep 19, 2024

Sep 19, 2024

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases - Kilgore News Herald

Sep 19, 2024

Sep 19, 2024

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 4.8% - MarketBeat

Sep 19, 2024